Revenue: As of FY2025 Q3, the actual value is USD 4.121 M, beating the estimate of USD 4 M.EPS: As of FY2025 Q3, the actual value is USD -0.32, missing the estimate of USD -0.3.EBIT: As of FY2025 Q3, the actual value is USD -22.11 M.<h3>Segment Revenue</h3><ul><li>Product Revenue: $2,756 thousand for the three months ended September 30, 2025, compared to $2,915 thousand for the same period in 2024, a decrease of 5%.</li><li>Service Revenue: $913 thousand for the three months ended September 30, 2025, compared to $661 thousand for the same period in 2024, an increase of 38%.</li><li>Related Party Revenue: $300 thousand for the three months ended September 30, 2025, compared to $366 thousand for the same period in 2024, a decrease of 18%.</li><li>Other Revenue: $152 thousand for the three months ended September 30, 2025, compared to $90 thousand for the same period in 2024, an increase of 69%.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: - $18,234 thousand for the three months ended September 30, 2025, compared to - $21,328 thousand for the same period in 2024, a decrease of 15%.</li><li>Gross Profit: $2,110 thousand for the three months ended September 30, 2025, compared to $1,938 thousand for the same period in 2024, an increase of 9%.</li><li>Operating Expenses: $21,456 thousand for the three months ended September 30, 2025, compared to $26,263 thousand for the same period in 2024, a decrease of 18%.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $33,641 thousand for the nine months ended September 30, 2025, compared to - $34,652 thousand for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $48,572 thousand for the nine months ended September 30, 2025, compared to $50,012 thousand for the same period in 2024.</li><li>Net Cash Used in Financing Activities: - $10,711 thousand for the nine months ended September 30, 2025, compared to - $10,237 thousand for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Revenue from International Markets: 48% of total revenue for the three months ended September 30, 2025, was generated outside of the United States, primarily from countries in Asia and Europe.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Seer, Inc. plans to continue commercializing the Proteograph Product Suite, focusing on growing adoption by the research community, expanding the installed base, and increasing utilization to generate revenue from the purchase of Proteograph consumables.</li><li>Non-Core Business: The company is investing in PrognomiQ, Inc., a related party, to help enable the growth of ecosystems around new applications that leverage the Proteograph solution for unbiased, deep, and large-scale proteomic information.</li></ul><h3>Priority</h3><ul><li>The company expects to continue to incur significant losses and does not expect positive cash flows from operations for the foreseeable future.</li></ul>

Seer | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 4.121 M